Connor, Clark & Lunn Investment Management Ltd.

Position in FATE — Fate Therapeutics Inc

CIK 1596800 VANCOUVER, A1

Position in FATE

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$563,742

+$454,740 QoQ

Shares Held

469,785

+322.4% QoQ

Ownership

0.403%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2020

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. FATE ranks #81 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$563,742	469,785	+322.4%	Shares	Sole	2026-05-11
2025-12-31	$109,002	111,227	-70.8%	Shares	Sole	2026-02-10
2022-12-31	$3,842,897	380,862	+27.0%	Shares	Sole	2023-02-10
2022-09-30	$6,718,831	299,814	+453.4%	Shares	Sole	2022-11-10
2022-06-30	$1,342,456	54,175	+606.8%	Shares	Sole	2022-08-05
2022-03-31	$297,172	7,665	-89.2%	Shares	Sole	2022-05-12
2021-06-30	$6,178,059	71,184	+10.9%	Shares	Sole	2021-08-12
2021-03-31	$5,292,053	64,185	+95.8%	Shares	Sole	2021-05-13
2020-12-31	$2,980,230	32,775	+355.0%	Shares	Sole	2021-02-16
2020-09-30	$287,943	7,204	—	Shares	Sole	2020-11-12
No filing history on record for this holder in this stock.